

Virginia CDC Paul Coverdell National Acute Stroke Program (CDC PCNASP)

Updates

Patrick Wiggins, MPH
Disease Prevention Strategist,
Virginia Department of Health

October 15, 2021

Funded States

States with Continued Funding

- Georgia
- Massachusetts
- Michigan
- Minnesota
- New York
- Ohio
- Wisconsin

Newly Funded States

- Arkansas
- Florida
- Hawaii
- Kentucky
- North Carolina
- Virginia

Coverdell Goals and Logic Model

DP21-2102 Coverdell Program Logic Model (NOFO, page 5)

Strategy	Short Term Outcomes	Intermediate Outcomes	Long Term Outcomes
<i>Track and Monitor Clinical Measures to Improve Data Infrastructure Across Stroke Systems of Care</i>	Increased measurement, tracking, and assessment of data across stroke systems of care for those at highest risk for stroke events and stroke patients	Increased linkage and usage of data across stroke systems of care for those at highest risk for stroke events and stroke patients	Increased access to care and improved quality of care for stroke patients Decreased disparities in access to and quality of care for populations at highest risk for stroke events
<i>Implement a Team-Based Approach to Enhance Quality of Care for Those at Highest Risk for Stroke Events and Stroke Patients Across Systems of Care</i>	Increased implementation of data-driven Quality Improvement activities across stroke systems of care for those at highest risk for stroke events and stroke patients	Increased coordination of care across stroke systems of care for those at highest risk for stroke events and stroke patients	
<i>Link Community Resources and Clinical Services That Support Those at Highest Risk for Stroke Events and Stroke Patients Across Systems of Care</i>	Increased establishment of community resources and clinical services for those at highest risk for stroke events and stroke patients across stroke systems of care	Increased provision of community resources and clinical services to those at highest risk for stroke events and stroke patients across stroke systems of care	

New VDH Stroke Registry Coordinator



Kathryn Funk, AGACNP-BC, MSN, SCRNP, CNRN

CDC PCNASP Data Elements

Changes to PCNASP Data Elements

	Previous Measures	Deleted	Additions	Total
Pre-Hospital	49	41	0	8
In-Hospital	271	147	31	155
Post-Hospital	86	86	0	0

Added PCNASP Data Elements

In-Hospital Data

Item	Variable Name	Description
Thrombolytic Treatment	<TrmALT>	Thrombolytic used: Alteplase (Class 1 evidence)
	<TrmALds>	Alteplase, total dose:
	<TrmTNK>	Thrombolytic used: Tenecteplase (Class 2b evidence)
	<TrmTNds>	Tenecteplase, total dose:
	<TrmTNRsn>	Reason for selecting tenecteplase instead of alteplase:
	<TrmExtnd>	If IV thrombolytic administered beyond 4.5-hour, was imaging used to identify eligibility?
	<TrmIVTAT>	If yes, select thrombolytic administered at outside hospital or Mobile Stroke Unit:
IV tPa Delay	<DelayRsn>	Eligibility or Medical reason(s) documented as the cause for delay in thrombolytic administration: Need for additional PPE for suspected/ confirmed infectious disease
Documented past medical history of any of the following: (check all that apply)	<MedHisEC>	Is there history of E-Cigarette Use (Vaping)? (Use of electronic nicotine delivery system or electronic cigarettes (e-cigarettes))
	<MedHisDT>	Medical history of dementia?
	<MH_EID>	HX of Emerging Infectious Disease
	<MH_COV1>	SARS-COV-1
	<MH_COV2>	SARS-COV-2 (COVID-19)
	<MH_MERS>	MERS
	<MH_OTH>	Other infectious respiratory pathogen
Other Complications	<DVTDocYN>	Did patient experience a DVT or pulmonary embolus (PE) during this admission?

Added PCNASP Data Elements

Active bacterial or viral infection at admission or during hospitalization*	<Inf_Cold>	Seasonal cold or flu
	<Inf_Flu>	Influenza
	<Inf_BAC>	Bacterial infection
	<Inf_OTH>	Other viral infection
	<Inf_EmID>	Emerging Infectious Disease
	<Inf_COV1>	SARS-COV-1
	<Inf_COV2>	SARS-COV-2 (COVID-19)
	<Inf_MERS>	MERS
	<Inf_OEID>	Other Emerging Infectious Disease
	<Inf_NONE>	None/ND
Lipid Treatment	<LipNone>	No cholesterol reducing treatment prescribed at discharge
	<LipFibr>	Cholesterol reducing treatment prescribed - Fibrate
	<LipNiacn>	Cholesterol reducing treatment prescribed - Niacin
	<LipAbsIn>	Cholesterol reducing treatment prescribed – Absorption inhibitor
	<LipPCSK>	Cholesterol reducing treatment prescribed – PCSK9 inhibitor

*= All variables under this item name have been added to be collected under DP21-2102.

Note: In-Hospital Data had 31 additions.

Final PCNASP Data Elements

Pre-Hospital

Item	Number	Variable Name	Text Prompt	Field Type	Legal Values	Notes
Scene Arrival	1	Pre-1a	<ScnArrD>		--/--/----- Date MMDDYYYY	
	2	Pre-1b	<ScnArrT>		__:__:__ Time HHMM	
Scene Departure	3	Pre-2a	<ScnDptD>		--/--/----- Date MMDDYYYY	
	4	Pre-2b	<ScnDptT>		__:__:__ Time HHMM	
Patient Age	5	Pre-3a	<Age>	Age _ _ _ _ years	Numeric ### = 3-digit 0 < age < 125	Prepopulated from in-hospital data
Patient Gender	6	Pre-4a	<Gender>	Gender	Numeric # = 1-digit 1 - Male; 2 - Female; 3 - Unknown	Select only 1 gender. Prepopulated from in-hospital data
Pre-hospital stroke screen performed	7	Pre-5a	<StkScn>	Did EMS perform a pre-hospital stroke screen?	Numeric # = 1-digit 1 - Yes; 2- No 3- Not Documented	
	8	Pre-5b	<EMSGlu>	Glucose level	Numeric # = 3-digit	*GWTG:mg/dL; for glucometers that don't produce a numeric value enter 600 for high and 20 for low

Final PCNASP Data Elements

In-Hospital

Category	Data Elements
Demographic	Age, Gender, Race, Ethnicity, Health Insurance
Intake	EMS Notification, Hospital Arrival, Comfort Measures, Medications
Medical History	DM, Prior Stroke, TIA, Carotid Stenosis, MI or CAD, PAD, Valve Prosthesis, CHF, Sickle Cell Disease, Pregnancy, A-fib, Telestroke, e-Cigarette, Dyslipidemia, HTN, Dementia, Emerging Infectious Disease, SARS-COV-1, SARS-COV-2, MERS, Other infectious respiratory pathogen.
Admission	Date Admitted, Ambulatory status prior to stroke/TIA, Symptoms completely resolve
Imaging	Brain Imaging performed after arrival, CT/MRI, Date and Time, Findings, Acute Vascular or Perfusion Imaging performed
Stroke Onset	Date and time of last known well, patient discovery, NIH Stroke Scale performed, NIH score
Thrombolytic Treatment	IV thrombolytic initiated, date and time, type of thrombolytic used (Alteplase, Tenecteplase) and dose, reasoning if tenecteplase, Imaging if beyond 4.5 hour window, IV thrombolytic at outside hospital or EMS mobile stroke unit, catheter-based treatment, Date and time of IA alteplase or MER initiation at hospital

Final PCNASP Data Elements

In-Hospital

Category	Data Elements
Complications	Complications of thrombolytic therapy, Reasons for no tPA 0-3 hour window, Exclusions, IV tPA delay
Other Treatment Options	Early Antithrombotics, VTE Prophylaxis, Other Therapeutic Anticoagulation
Hospital Discharge	Dysphagia Screening, Other In-Hospital Complications, Other Complications, Active bacterial or viral infection at admission or during hospitalization, Date of Discharge, Principal discharge ICD-10-CM diagnosis, Clinical Diagnosis related to stroke, Discharge Disposition, Functional Status at Discharge, Antihypertensive treatment, Lipid Treatment, Atrial Fibrillation, Antithrombotics at Discharge, Smoking Counseling, Stroke Education, Rehabilitation

Questions and Answers

Contact Information:

Patrick.Wiggins@vdh.Virginia.gov

and

Kathryn.Funk@vdh.Virginia.gov